208 related articles for article (PubMed ID: 22111015)
1. Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents.
Karlsson T
ISRN Hematol; 2011; 2011():108397. PubMed ID: 22111015
[TBL] [Abstract][Full Text] [Related]
2. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
4. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
5. Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.
Laermans J; Van Remoortel H; Avau B; Bekkering G; Georgsen J; Manzini PM; Meybohm P; Ozier Y; De Buck E; Compernolle V; Vandekerckhove P
Syst Rev; 2022 Oct; 11(1):224. PubMed ID: 36253838
[TBL] [Abstract][Full Text] [Related]
6. The role of iron supplementation during epoietin treatment for cancer-related anemia.
Hedenus M; Birgegård G
Med Oncol; 2009; 26(1):105-15. PubMed ID: 18473194
[TBL] [Abstract][Full Text] [Related]
7. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
[TBL] [Abstract][Full Text] [Related]
8. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
Luo J; Jensen DE; Maroni BJ; Brunelli SM
Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
[TBL] [Abstract][Full Text] [Related]
9. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
[TBL] [Abstract][Full Text] [Related]
10. Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?
Shander A; Spence RK; Auerbach M
Transfusion; 2010 Mar; 50(3):719-32. PubMed ID: 19919555
[TBL] [Abstract][Full Text] [Related]
11. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T; Nitta K
Contrib Nephrol; 2015; 185():76-86. PubMed ID: 26023017
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?
Dahl NV; Henry DH; Coyne DW
Semin Dial; 2008; 21(3):210-1. PubMed ID: 18397204
[TBL] [Abstract][Full Text] [Related]
13. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Wyck DV; Meier Y; Larroque S; Perrin A; Roger SD
Clin Nephrol; 2017 Dec; 88(12):301-310. PubMed ID: 29092739
[TBL] [Abstract][Full Text] [Related]
16. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation.
Adamson JW
Adv Chronic Kidney Dis; 2009 Mar; 16(2):76-82. PubMed ID: 19233066
[TBL] [Abstract][Full Text] [Related]
17. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agent hyporesponsiveness.
Johnson DW; Pollock CA; Macdougall IC
Nephrology (Carlton); 2007 Aug; 12(4):321-30. PubMed ID: 17635745
[TBL] [Abstract][Full Text] [Related]
19. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy.
Rodgers GM; Gilreath JA
Acta Haematol; 2019; 142(1):13-20. PubMed ID: 30970366
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
